Thruvision shares surge 46% to 0.91p on £3m Asian airport contract
Thruvision Group PLC (AIM:THRU, OTC:DIGTF) shares jumped 46% to 0.91p after the security screening group landed its largest contract in Asia to date. The AIM-listed company said its principal regional partner has won a deal to deploy Thruvision systems across several major airports in South-East Asia, generating more than £3 million of revenue.
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating
Cavendish sees almost fivefold upside in Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) after regulators extended the Verbier licence, giving the partners more time to advance an integrated Greater Buchan Area development. The broker has repeated a Buy recommendation and 537p price target, representing 388% upside from the AIM-listed company's 110p share price.
Cavendish sees 18-fold upside at 88 Energy on Alaska prospect scale
Cavendish has reiterated its buy rating and 19.8p target price on 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), implying significant untapped upside from the current 1.02p share price. The AIM-listed oil and gas explorer's South Prudhoe acreage on Alaska's North Slope now holds 768.9 million barrels of gross prospective resources, of which 640.7 million barrels are net to the company.
Seeing Machines wins European carmaker deal as EU driver monitoring rules come into force
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z), the AIM-listed computer vision company, has secured a new driver and occupant monitoring contract with a European carmaker as fresh European Union safety rules take effect. The award, won through an existing Tier 1 supplier, is expected to generate around $5 million in lifetime revenue.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
Coiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansion
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), a clinical-stage oncology company developing medicines for hard-to-treat cancers, has created a new oral formulation of its lead drug candidate designed to improve how the treatment is absorbed by the body. The AIM-listed company said it expects to dose the first patient with the reformulated version of AO-252 this month.
Phoenix Copper shares drop on discount equity raise
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while warning that further funding will still be needed before the end of September. The AIM-listed Idaho copper developer is proposing to issue around 460 million new shares at 0.5p each, a 54.5% discount to the 1.1p closing mid-market price on 2 July.
Greatland Resources ramp-up continued through June 2026
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP) told investors that its full-year gold production topped guidance after a June quarter that also lifted its cash balance to almost US$1.3 billion with no debt. The AIM- and ASX-listed miner produced 79,099 ounces of gold and 3,573 tonnes of copper in the three months to 30 June 2026, taking full-year production to 328,986 ounces of gold and 14,594 tonnes of copper.
Coiled Therapeutics appoints biotech veteran Craig Tooman to board
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the AIM-listed clinical-stage oncology company, has appointed Craig Tooman as an independent non-executive director with effect from 25 June. Tooman most recently served as president, chief executive and board director of Silence Therapeutics, the Nasdaq-listed siRNA company.
OUST's AIM Partnership Validates Rev8's Commercial Promise
Ouster's AIM supply deal puts its Rev8 lidar into autonomous mining and construction fleets, offering a high-profile test of its commercial potential.
Metals One builds 5.57% stake in newly listed Talon Resources
Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF), the gold and uranium developer and investor, has built a 5.57% stake in Talon Resources. The holding was confirmed as Talon began trading on AIM on Tuesday.
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset centred on cost reduction and a shift towards partner-led commercialisation of its Parsortix platform.
